Cancer-associated fibroblast activation protein in Appalachian women with uterine cervix cancer - Takeaways - MDSpire

Cancer-associated fibroblast activation protein in Appalachian women with uterine cervix cancer

  • By

  • Denise Fabian

  • Morgan S. Levy

  • Dava W. Piecoro

  • Dana Napier

  • Rachel W. Miller

  • Charles A. Kunos

  • June 1, 2026

  • 0 min

Share

  • 1

    The study assessed FAP expression in 37 uterine cervix cancer tumors to evaluate the potential of [212Pb]Pb-PSV-359 as a treatment.

  • 2

    Eighty-two percent of tumors with evaluable desmoplastic stroma expressed FAP, indicating a strong presence of cancer-associated fibroblasts.

  • 3

    Fifty-nine percent of the tumors scored an immunoreactive score of six or higher, suggesting significant FAP immunoreactivity.

  • 4

    Stage IVB and metastatic tumors showed the highest FAP expression, with 76% of these tumors having cancer-associated fibroblasts expressing FAP.

  • 5

    The findings support the potential use of FAP as a biomarker for targeting radiopharmaceutical therapy in advanced uterine cervix cancer.

Original Source(s)

Cancer-associated fibroblast activation protein in Appalachian women with uterine cervix cancer

  • by Denise Fabian, Morgan S. Levy, Dava W. Piecoro, Dana Napier, Rachel W. Miller, Charles A. Kunos

  • June 1, 2026

Related Content

HPV-specific innovations and controversies in therapeutic strategies for HPV-associated oropharyngeal carcinoma

Case Report: A rare triad of neoplasms: navigating synchronous accessory breast cancer, papillary thyroid carcinoma, and inflammatory nasal papilloma

Stimuli-responsive nanoplatforms for sonodynamic immunotherapy: opportunities and challenges in cancer treatment